Optimal dose of etanercept in the treatment of rheumatoid arthritis
Elizabeth Mary Curtis, Jonathan Lewis MarksDepartment of Rheumatology, University Hospital Southampton, Southampton, Hampshire, UKAbstract: Etanercept (ETN) is one of a number of biological therapies targeting the proinflammatory cytokine tumor necrosis factor-alpha that have demonstrated efficacy...
Guardado en:
Autores principales: | Curtis EM, Marks JL |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d11f11d8cc3d4f50ad7576ab43040d03 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis
por: Michihito Sato, et al.
Publicado: (2011) -
Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
por: Franz Thiele, et al.
Publicado: (2021) -
Certolizumab in the long-term treatment of rheumatoid arthritis
por: Scott DL, et al.
Publicado: (2011) -
Long-term treatment of rheumatoid arthritis with adalimumab
por: Murdaca G, et al.
Publicado: (2013) -
New and emerging therapies for the treatment of rheumatoid arthritis
por: Michael G Feely
Publicado: (2010)